Icatibant Gp-Pharm

Icatibant, the active ingredient in Icatibant Gp-Pharm, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for subcutaneous use. It treats hereditary angioedema (HAE) attacks in patients with this rare genetic disorder.

GNH USA supplies Icatibant Gp-Pharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a bradykinin B2 receptor antagonist used in the management of hereditary angioedema.

- Hereditary angioedema (HAE) attacks: provides rapid relief of swelling episodes by blocking bradykinin‑mediated vascular permeability.

Icatibant may cause a range of adverse reactions, most of which are related to its subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: redness around the injection area. - Nausea: occasional feeling of queasiness. - Headache: transient head discomfort. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hypotension: sudden drop in blood pressure. - Angioedema: new swelling episodes unrelated to HAE. - Thrombocytopenia: reduced platelet count. - Severe infection at injection site: signs of cellulitis or abscess formation.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown safety; weigh benefits against possible infant exposure. - Renal impairment: monitor patients as clearance may be reduced. - Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced effects. - Estrogen‑containing therapies: may potentiate bradykinin‑mediated reactions; monitor closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: increase bradykinin levels and may heighten risk of angioedema. - Neprilysin inhibitors: similarly raise bradykinin concentrations. - Estrogen‑containing oral contraceptives: may exacerbate bradykinin‑mediated swelling.

Moderate Interactions (Monitor Closely): - NSAIDs: can affect renal function and alter drug clearance. - Diuretics: may influence blood pressure response. - Other antihypertensives: monitor for additive hypotensive effects. - Corticosteroids: may mask early signs of infection at injection site. - Additional B2 receptor antagonists: assess cumulative pharmacologic impact.